Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

PlexusDx vs Revel RX

By GLP-1 ScorecardUpdated

PlexusDxFactor scores not reassessed.
Site position #112

Lower score

Revel RXFactor scores not reassessed.
Site position #48

Higher score

Score comparison

Revel RX has the higher recorded score — 77.3/100 to 67.7/100.

Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel Rx advertises the same monthly price across doses and no separate membership fee. Its refund policy still refers to canceling a subscription.

Before you choose

Before comparing the headline prices, the PlexusDx review and the Revel RX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, PlexusDx vs RxPros and Potere Health MD vs Revel RX compare each of them with another graded program, and the list of alternatives to PlexusDx ranks the programs closest to PlexusDx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueRevel RX +22
74
96
Dose & formulationRevel RX +8
64
72
Clinical oversightRevel RX +10
74
84
Labs & monitoringRevel RX +1
52
53
FulfillmentRevel RX +3
78
81
Contract termsEven
55
55
PlexusDx · top barRevel RX · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricPlexusDxRevel RX
WeighScore67.7/10077.3/100
GradeCC+
Site position#112#48
Semaglutide$99/mo (12-month plan; compounded)$89/mo (advertised all doses, compounded)
Tirzepatide$129/mo (12-month plan; compounded)$155/mo (advertised all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
PlexusDx

Site position #112 · C

Factor scores not reassessed.

Strengths

  • Licensed providers available in all 50 states
  • Range of options including microdose GLP-1 from $69/mo on a 12-month plan
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

What to consider

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • The advertised $99 semaglutide and $129 tirzepatide rates require a 12-month plan; shorter-term prices were not visible
  • No insurance accepted
Revel RX

Site position #48 · C+

Factor scores not reassessed.

Strengths

  • Publishes prices for both compounded medications
  • Advertises clinician review and included shipping
  • Provides written instructions for canceling before shipment

What to consider

  • The refund policy treats charged orders already handed to the carrier as final
  • No dispensing pharmacy assignment or state eligibility was verified for an individual order

Featured provider

PlexusDx

Factor scores not reassessed.

PlexusDx scores 67.7/100 (C). PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard